Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Outlook Therapeutics To Revise Ophthalmic Bevacizumab BLA In Light Of FDA Request

    Outlook Therapeutics announced today that the FDA has requested additional information in order to complete the filing of the company's BLA for LYTENAVA. LYTENAVA, or ONS-5010...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Pennsylvania Department Of Health Clarifies Clinical Laboratory Law

    Pennsylvania Act 122 amended the Pennsylvania Clinical Laboratory Act to, among other things, impose licensure requirements on out of state clinical laboratories.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Fox Rothschild LLP
Fox Rothschild LLP
  • Article

    Podcast: Engineered Foods And Patent Eligibility Issues

    Engineered natural products like lab-grown meat and synthetic milks represent the next step in food science.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Podcast

    Profiles In Courage: Bill Lee (Podcast)

    Voices of Asian America's Profiles in Courage podcast shared an interview with Partner Bill Lee about his experiences as a leading Asian American in the legal industry.
    United StatesFood, Drugs, Healthcare, Life Sciences
    WilmerHale
    WilmerHale
  • Article

    Proposed HELP Committee Bill Aims to Incentivize Development of Ebola Treatments and Vaccines

    In light of the recent Ebola outbreak and concerns over health safety, members of the U.S. Senate’s Health, Education, Labor, and Pensions (HELP) Committee have introduced a bill that would add Ebola to the Food and Drug Administration’s (FDA) ..
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    Regulatory Update On Alvotech's AVT02, A High-Concentration Interchangeable Adalimumab Biosimilar

    On September 20, Alvotech announced that FDA has accepted the resubmission of its Biologics License Application (BLA) for AVT02, a high concentration, interchangeable biosimilar...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    RELEUKO Receives FDA Approval

    Amneal Pharmaceuticals and Kashiv Biosciences have announced that their RELEUKO (filgrastim-ayow) biosimilar recently received FDA approval, making it the third filgrastim biosimilar approved...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Researchers Find Certain Biodegrading Nano Quantum Dots Can Release Toxins Into The Environment

    Researchers at the University of Buffalo have found that cadmium selenide quantum dots degrade in soil, releasing toxic cadmium and selenium ions into the environment.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Day Pitney LLP
    Day Pitney LLP
  • Article

    SaMD Series: The Interplay Between IP And FDA Submissions

    Software as a Medical Device – also referred to as SaMD – is one of the fastest growing innovations in the medical device industry
    United StatesFood, Drugs, Healthcare, Life Sciences
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Article

    Sandoz's High Concentration Adalimumab Biosimilar Application Accepted By EMA

    Sandoz recently announced that the EMA (European Medicines Agency) has accepted its application for a 100 mg/ml citrate-free formulation of its biosimilar HYRIMOZ® (adalimumab).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Sandoz Announces Approval For Biosimilar Hyrimoz® (adalimumab-adaz)

    On March 21, 2023, Sandoz, announced FDA approval of its citrate-free high-concentration formulation (HCF) of its biosimilar HYRIMOZ® (adalimumab-adaz) injection.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Sandoz Announces New Global "Act4Biosimilars" Initiative

    On May 31, 2022, Sandoz announced the launch of a new global initiative called "Act4Biosimilars" to help address health inequity and inequality worldwide.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    STADA And SBP Group Launch Biosimilars Partnership

    STADA and Sino Biopharmaceutical Limited have formed a strategic partnership to develop and commercialize biosimilar medications across Europe and neighboring regions. The collaboration focuses on bringing biosimilar alternatives to market, beginning with a pembrolizumab biosimilar targeting multiple cancer indications, with plans to expand into additional oncology and immunology treatments.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    States Continue Protest Zohydro Approval; Massachusetts Bans Sales

    Several states have protested FDA's approval of hydrocodone drug Zohydro ER based on concerns that it has a a higher-than-acceptable risk of abuse.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Supreme Court Declines To Review Sequenom Ruling

    While denying certiorari usually maintains the status quo, the denial here may lead the U.S. Patent and Trademark Office (USPTO) to revisit the subject matter eligibility examples for diagnostic methods released May 4, 2016.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Teva And Prestige Biopharma Enter Licensing Agreement To Commercialize Their Trastuzumab Biosimilar

    On October 20, 2025, Teva Pharmaceuticals International GmbH ("Teva") announced a licensing agreement with Prestige BioPharma Ltd. ("Prestige BioPharma") to commercialize TUZNUE® (trastuzumab), a biosimilar to Genentech's HERCEPTIN (trastuzumab), in a majority of European countries.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    The Pharmaceutical Pipeline And The Changing Nature Of Innovation And Collaboration In A COVID-19 World

    Will Garvin, Barbara Binzak Blumenfeld, and Matt Fedowitz, shareholders in the firm's Life Sciences Industry Group—along with Grant Strachan of Brodies Solicitors in Scotland—will be presenting at the TerraLex 2020 Virtual Global Meeting on November 13.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Buchanan Ingersoll & Rooney
    Buchanan Ingersoll & Rooney
  • Article

    Theft Of Unencrypted Flash Drive Causes OCR To Issue Settlement And Corrective Action Plan For Physician Practice

    The Department of Health and Human Services’ Office for Civil Rights (OCR) opened an investigation of Adult & Pediatric Dermatology, P.C. (APDerm) after a report was made regarding the theft of an unencrypted flash drive.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    Update On Nanotechnology Class 977 Patent Filings In 2013 – The Patent Race Slows An Ounce?

    An insight at how the class 977 patent filings are coming for the new year.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Urgent: Time Flying In 2013 As First-To-File And New Fee Systems Now Arriving!

    An updated URGENT alert that the new U.S. first-to-file patent reform laws are now less than two weeks away.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Showing 301–320 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics